MARKET

VERU

VERU

Veru
NASDAQ
0.4511
-0.0404
-8.22%
After Hours: 0.4699 +0.0188 +4.17% 19:45 03/13 EDT
OPEN
0.4830
PREV CLOSE
0.4915
HIGH
0.4976
LOW
0.4510
VOLUME
1.59M
TURNOVER
--
52 WEEK HIGH
1.920
52 WEEK LOW
0.4510
MARKET CAP
66.03M
P/E (TTM)
-1.7172
1D
5D
1M
3M
1Y
5Y
1D
Viking, other obesity players fall following Novo Nordisk CagriSema results
Seeking Alpha · 3d ago
Weekly Report: what happened at VERU last week (0303-0307)?
Weekly Report · 3d ago
Weight-loss drug battle: Who are the latest players involved
Seeking Alpha · 5d ago
Weekly Report: what happened at VERU last week (0224-0228)?
Weekly Report · 03/03 11:32
Based on the provided financial report, the title of the article is likely: "VERU INC. 10-K (Annual Report) for the fiscal year ended September 30, 2024" This title indicates that the report is an annual report filed by VERU INC. with the Securities and Exchange Commission (SEC) for the fiscal year ended September 30, 2024.
Press release · 03/03 09:59
Weekly Report: what happened at VERU last week (0217-0221)?
Weekly Report · 02/24 11:31
Director Makes Bold Move with Major Veru Stock Purchase!
TipRanks · 02/21 02:04
FOCUS-Next generation weight loss drugs aim to save muscle
Reuters · 02/19 11:00
More
About VERU
More
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Recently
Symbol
Price
%Change

Webull offers Veru Inc stock information, including NASDAQ: VERU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERU stock methods without spending real money on the virtual paper trading platform.